...
首页> 外文期刊>Medicine. >Zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: A case report and literature review
【24h】

Zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: A case report and literature review

机译:肝细胞癌骨转移与阿帕替尼的治疗疗效:一例报告并文献复习

获取原文

摘要

Rationale: Hepatocellular carcinoma (HCC) metastases to the zygomatic bone are extremely uncommon, and the treatment of target drugs against such case is unknown. Patient concerns: A 48-year-old male patient was admitted to our hospital under suspicion of an advanced liver tumor due to an increase in levels of alpha-fetoprotein (AFP) after radiofrequency ablation for independent nodule in his liver 1 month before. He had a hepatitis B virus (HBV) history for 20 years without treatment. Diagnosis and interventions: A diagnosis of primary HCC was made based on pathological examination following right hepatectomy. Seven months after the surgery, a mass in S8 was identified and treated by ARF. Twenty days later, a right zygomatic mass was observed and the incisional biopsy revealed metastasis from HCC. Due to side effects of chemotherapy, the metastatic zygomatic mass was treated with radioactive seed implantation. Despite these interventions, there was steady increase in AFP values as well as increase in size of the zygomatic mass. Hence, the patient was started on apatinib with a dose of 500 mg/day from 1 to 28 days per cycle for a duration of 10 months. Outcomes: The AFP values were significantly decreased but the size of the zygomatic mass continued to increase indicating progression of disease. But the progression-free survival was more than 10 months. The patient exhibited adverse reactions which were controllable by symptomatic treatments. As of last follow-up, the patient is unwell with pain in the face, blurred vision in the right eye, dyscrasia, and exhibited difficulty in opening his mouth. Lessons: HCC metastases to the zygomatic bone are very aggressive with a very low incidence and immunohistochemistry is useful diagnostic indicators. Still now, there is no optimal treatment strategy for these patients. Apatinib may be a promising drug in the treatment of HCC metastases to the zygomatic bone .
机译:理由:肝细胞癌(HCC)转移至骨的情况极为罕见,针对这种情况的靶标药物的治疗尚不清楚。患者担忧:一名48岁的男性患者因射频消融1个月前肝脏中的独立结节后甲胎蛋白(AFP)水平升高,被怀疑患有晚期肝脏肿瘤而入院。他有20年的乙肝病毒病史,未经治疗。诊断和干预:右肝切除术后根据病理检查诊断为原发性肝癌。手术七个月后,发现了S8肿块并通过ARF治疗。二十天后,观察到右骨肿块,切开活检发现有肝癌转移。由于化学疗法的副作用,用放射性种子植入治疗了转移性radio骨肿块。尽管采取了这些干预措施,AFP值仍在稳定增加,而the骨肿块的大小却在不断增加。因此,患者开始于每个周期1至28天以500 mg /天的剂量服用apatinib,持续10个月。结果:AFP值明显降低,但zy突肿块的大小持续增加,表明疾病进展。但是无进展生存期超过10个月。患者表现出可通过对症治疗控制的不良反应。在上次随访中,患者的不适是面部疼痛,右眼视力模糊,发育不良和张口困难。经验教训:HCC转移到骨的侵袭性非常强,发生率非常低,免疫组织化学是有用的诊断指标。到目前为止,仍没有针对这些患者的最佳治疗策略。阿帕替尼可能是治疗CC骨肝癌转移的有前途的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号